SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Summer Interns

IP-Watch interns talk about their Geneva experience in summer 2013. 2:42.

Inside Views

Submit ideas to info [at] ip-watch [dot] ch!

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Analysis: Monkey In The Middle Of Selfie Copyright Dispute

The recent case of a monkey selfie that went viral on the web raised thorny issues of ownership between a (human) photographer and Wikimedia. Two attorneys from Morrison & Foerster sort out the relevant copyright law.


Latest Comments
  • are you aware that within the photographic industr... »
  • A VPN is a virtual private network, which generall... »

  • For IPW Subscribers

    A directory of IP delegates in Geneva. Read more>

    A guide to Geneva-based public health and intellectual property organisations. Read More >


    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >

    Biovision: Personalised Medicine, Climate Change, Sustainability Need Innovation

    Published on 27 March 2013 @ 6:45 pm

    By , Intellectual Property Watch

    Biovision sessionsLyon, France – Biovision, a biennial international event on life sciences, brought together some 3,000 participants this week to discuss and compare experiences in different fields, including personalised medicine, how best to use natural resources and the impact of climate change on food security. Open innovation was presented as a way forward, and the role of companies in mitigation was deemed important but with ethics.

    Biovision took place from 24-26 March and gathered policymakers, academics, the private sector and civil society.

    One session looked at how to bring personalised medicine into action. Samir Brahmachari, director general of the Council of Scientific & Industrial Research and secretary to the Indian Department of Science and Industrial Research, talked about open source drug discovery.

    In drug discovery for infectious disease we are falling behind and  need innovation, said Samir Brahmachari. (Photo Credit: Catherine Saez, IP-Watch)

    In drug discovery for infectious disease we are falling behind, and we need innovation, said Samir Brahmachari. (Photo Credit: Catherine Saez, IP-Watch)

    Open innovation embodies the notion that in the new economy, sharing is necessary, he said, mentioning that for centuries innovation was open in India, citing the Kama Sutra or Ayurveda.

    The premise of open source is that access to affordable healthcare is a right for all, Brahmachari said. The cost of DNA sequencing and synthesis dropped significantly in recent years, while research and development costs took the opposite trend, he said. “It just does not make any sense,” he said. “We are doing unnecessary research on poor drug candidates,” he said, adding that “Over 80 percent of listed failures are due to poor efficacy and safety,” he said.

    Brahmachari introduced the Open Source Drug Discovery (OSDD), which is an Indian publicly funded organisation. According to its website, OSDD is a “Council of Scientific and Industrial Research (CSIR) India led initiative,” and holds a variety of patents in biological, chemical, engineering, physical and environmental science.

    Launched in 2008, the OSDD’s first target is tuberculosis, due to its high incidence and mortality rates in India and other developing countries. “The OSDD model is scalable and applicable to all diseases without market,” the website says.

    Brahmachari said all contributions from researchers on the OSDD portal are attributed to the authors. The OSDD licence considers information available on the portal as “protected collective information,” and this information is held on behalf of OSDD by CSIR “as a trustee holder with legal powers and authority for legal action,” according to the OSDD. “We really need to have a balanced view between health as a right and health as a business,” Brahmachari said.

    Human Genome Deciphered, But Not Personalised Medicine

    For Stephen Friend, president of US-based Sage Bionetworks, another speaker at the event, the public should not be led to believe that the progress accomplished in deciphering the human genome will amount to easy personalised medicine. “We are alchemists of medicine,” he said “we are not going to make sense of it until we actually understand the fundamental rules.”

    Among the problems met by research in this area is that “we have an entire universe of funding” for hypothesis-driven research, Friend said. In the United States, he added, it is difficult to get funded when not working on an hypothesis-driven research. In the world of data-driven medical research “there is a real risk of generalising from the particular,” he said, adding “We have all whole legions of tenured professors driving down their hypothesis-driven work which is not necessarily helping us,” he said.

    Sessions featured speakers coming from different sectors (Photo Credit: Catherine Saez, IP-Watch)

    Sessions featured speakers coming from different sectors (Photo Credit: Catherine Saez, IP-Watch)

    Another problem is that despite the amount of data delivered by the genomic revolution, without information from patients to match that genotypic information “we’ll not be able to sort it out,” he said.

    The complexity of personalised medicine could be helped by “four important mini-revolutions that have been going on,” he said: the ability to store data in one place and have it available from anywhere in the world; the ability for the public to do some research and share it; the ability to use the crowd to solve problems; and the ability to do top-down modelling.

    Climate Change, Sustainable Development

    During another session focusing on the impact of climate change on food resources, Marc Van Ameringen, executive director of Swiss-based non-governmental organisation GAIN, said that in the days of the green revolution, investments in IP in food security were seen as a public good. “But with that culture falling off the agenda for two and a half decades, it was really the private sector that has picked up most of the responsibility,” he said.

    Today, companies like Syngenta spend twice as much as the public-oriented Consultative Group on International Agricultural Research, Van Ameringen said. “So the private sector is absolutely critical.” The private sector should own IP but there is a public good element and “we need a dramatic investment in international agricultural research to represent that public good,” he said. “It is trickling back in from where it was but that is what we are missing today” We need private-public partnerships but the public part needs to be on the table.”

    Biovision also held a plenary session on using natural resources without consuming the planet. Feike Sijbesma, CEO of Royal DSM, a Dutch company active in health and nutrition, said the role of companies is “huge”, and increased in the last century “tremendously.” Companies have local, regional and global impact, and “the ability to destroy parts of this planet and they frequently do so… and the power to restore and do good for the world and they frequently do so,” he said.

    Feike Sijbesma: Companies should work for the different stakeholders and not only for their shareholders. (Photo Credit: Catherine Saez, IP-Watch)

    Feike Sijbesma: Companies should work for the different stakeholders and not only for their shareholders. (Photo Credit: Catherine Saez, IP-Watch)

    With power comes responsibility, and companies have some keys in hand to solve some of the problems the world faces, but they “should work for the different stakeholders and not only for their shareholders,” he said.

    The world is facing several challenges, among which is climate change, he said, but also an unsustainable distribution of wealth. Some 2 billion people out of the 7 billion of the planet go hungry and 1 billion people are suffering from diseases such as obesity, and diabetes and they consume half of the world’s pharmaceutical production, he said.

    Anne Glover, chief scientific advisor to the President at the European Commission, said the generation of knowledge is key, but knowledge is useless if “we don’t communicate it.” She said citizens could make requests to their politicians, business and policymakers, as “it is our planet.” But “citizens also have the responsibility to engage in the knowledge that is being generated,” she said.

    Business, according to Glover, “is incredibly important in delivering the future that we need, but we do trust business?”

    “If we have a very strong ethical framework for business it would give citizens a strong feeling that knowledge is being used appropriately and with their agreement, to deliver solutions for major problems in the future,” she said, but it would also be good for business since it gives them a leveled playing field to operate if there is a strong code of ethics.

     

    Catherine Saez may be reached at info@ip-watch.ch.

     


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

     

     
    Your IP address is 54.83.229.255